AbCellera Biologics Inc. develops antibody-based medicines as a clinical-stage biotechnology company. Its updates center on antibody discovery and development programs in endocrinology, women’s health, immunology, oncology, and other areas, including work on complex targets such as GPCRs and ion channels.
Recurring news themes include clinical disclosures for ABCL635, an antibody therapeutic targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. Company announcements also cover financial results, earnings-call materials, investor conference participation, platform and manufacturing updates, and patent licensing or litigation-resolution developments.
AbCellera (Nasdaq: ABCL) will present at three investor conferences in March and April 2026: TD Cowen 46th Annual Health Care Conference on March 4, KeyBanc Capital Markets Healthcare Forum on March 17, and Bloom Burton & Co. Healthcare Investor Conference on April 21–22. A live audio webcast and replay will be posted on the company Investor Relations website closer to each date.
AbCellera (Nasdaq: ABCL) will report full year 2025 financial results on Tuesday, February 24, 2026. The company will host an earnings conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time the same day. A live audio webcast will be accessible via a link on AbCellera's Investor Relations website, and a replay will be available at the same link after the call.
AbCellera (Nasdaq: ABCL) announced dosing of the first patients in the Phase 2 portion of its Phase 1/2 trial of ABCL635, a potential first-in-class non-hormonal therapy for moderate-to-severe vasomotor symptoms (VMS) of menopause. The Phase 2 is a multicenter, randomized, double‑blind, placebo‑controlled Proof-of-Concept study in 80 postmenopausal women. The move to Phase 2 follows an interim review of safety, tolerability, and pharmacodynamic data from Phase 1 healthy volunteers and evidence of high target engagement. With Phase 2 enrollment underway, the company anticipates top-line results for both phases in Q3 2026.
AbCellera (Nasdaq: ABCL) announced a global settlement and patent license agreement with Bruker on December 18, 2025. As part of the deal, Bruker will pay $36 million up front and will make future royalty payments on sales of Bruker's Beacon® Optofluidic platform worldwide through the life of the licensed patents. The agreement resolves the companies' global patent litigation and grants Bruker a license to the covered patents.
AbCellera (Nasdaq: ABCL) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A live audio webcast will be available via a link posted on AbCellera's Investor Relations website, with a replay accessible after the presentation.
AbCellera (Nasdaq: ABCL) appointed Stephen Quake, D.Phil., to its Board of Directors as an independent director effective November 10, 2025.
Dr. Quake is a prominent scientist and entrepreneur with >300 publications, an h-index of 181, 80+ patents, leadership roles at Stanford and Caltech, and service as founding co-president and later head of science for the Chan Zuckerberg Biohub Network (launch budget ~$600 million). Concurrently, Andrew W. Lo, Ph.D., resigned after joining the board in December 2021 and serving on Audit and Nominating and Corporate Governance Committees.
AbCellera (Nasdaq: ABCL) reported Q3 2025 results for the period ended September 30, 2025. Key operational highlights include starting activities at a new clinical manufacturing facility, substantially completing platform investments, and appointing Sarah Noonberg, M.D., Ph.D. as chief medical officer.
Financials: Revenue $9.0M versus $6.5M a year earlier; net loss $57.1M ($(0.19) per share) versus $51.1M in Q3 2024. R&D spend rose to $55.0M, including $15.0M on two internal programs. Liquidity totaled approximately $680M including $523M cash and $159M government funding.
Operational metrics: 103 partner-initiated program starts with downstreams and 18 molecules in the clinic.
AbCellera (Nasdaq: ABCL) will participate in multiple investor conferences in November and December 2025.
Scheduled events: Truist Securities BioPharma Symposium on November 6, 2025; Stifel Healthcare Conference on November 11–13, 2025; Jefferies Global Healthcare Conference on November 18–20, 2025; and Piper Sandler 37th Annual Healthcare Conference on December 2–4, 2025. Visit the company Investor Relations website for additional information and access details.
AbCellera (NASDAQ:ABCL) has scheduled its third quarter 2025 financial results announcement for Thursday, November 6, 2025. The company will host an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on the same day. Investors can access the live audio webcast through AbCellera's Investor Relations website, where a replay will also be available after the call.
AbCellera (Nasdaq: ABCL) has appointed Dr. Sarah Noonberg as its first Chief Medical Officer. Dr. Noonberg, a board-certified physician-scientist with over 20 years of industry experience, brings extensive expertise in clinical development across various therapeutic areas including oncology, neuroscience, rare diseases, and gene therapy.
Previously serving as CMO at Metagenomi, where she helped secure a $100M IPO, Dr. Noonberg will now focus on advancing AbCellera's pipeline of antibody-based therapeutics. Her impressive background includes leadership roles at Maze Therapeutics, Nohla Therapeutics, Prothena Biosciences, and BioMarin, along with significant contributions to the development of XTANDI™ for prostate cancer at Medivation.